New-onset gastrointestinal disorders in COVID-19 patients 3.5 years post-infection in the inner-city population in the Bronx DOI Creative Commons

Sagar Changela,

Samad Ashraf,

Justin Y. Lu

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Dec. 30, 2024

This study examined the incidence, characteristics, and risk factors of new gastrointestinal disorders (GID) associated with SARS-CoV-2 infection up to 3.5 years post-infection. retrospective included 35,102 COVID-19 patients 682,594 contemporary non-COVID-19 without past medical history GID (controls) from Montefiore Health System in Bronx (3/1/2020 7/31/2023). Comparisons were made unmatched propensity-matched (1:2) controls. The primary outcome was which peptic ulcer, inflammatory bowel disease, irritable syndrome, diverticulosis, diverticulitis, biliary disease. Multivariate Cox proportional hazards model analysis performed adjustment for covariates. There 2,228 (6.34%) positive who developed compared 38,928 (5.70%) had an elevated developing (adjusted HR = 1.18 (95% CI 1.12-1.25) controls, after adjusting confounders that smoking, obesity, diabetes, hypertension. These findings underscore need additional research follow-up at-risk individuals post infection.

Language: Английский

Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021 DOI Creative Commons

Junyue Cen,

Qian Wang, Lin Cheng

et al.

The Journal of Headache and Pain, Journal Year: 2024, Volume and Issue: 25(1)

Published: June 6, 2024

Abstract Background Migraine, a neurological disorder with significant female predilection, is the leading cause of disability-adjusted life years (DALYs) in women childbearing age (WCBA). There currently lack comprehensive literature analysis on overall global burden and changing trends migraines WCBA. Methods This study extracted three main indicators, including prevalence, incidence, DALYs, related to migraine WCBA from Global Burden Disease(GBD) database 1990 2021. Our presented point estimates 95% uncertainty intervals (UIs). It evaluated using estimated annual percentage change (EAPC) change. Results In 2021, DALYs cases among were 493.94 million, 33.33 18.25 respectively, changes 48%, 43%, 47% compared 1990. Over past 32 years, prevalence rates globally have increased, an EAPC 0.03 (95% UI: 0.02 0.05) 0.04 0.05), while incidence decreased -0.07 -0.08 -0.05). Among 5 Socio-Demographic Index (SDI) regions, middle SDI region recorded highest WCBA, at 157.1 10.56 5.81 approximately one-third total. terms age, for group 15–19 5942.5 thousand, rate per 100,000 population 1957.02, all groups. The total number show increasing trend particularly 45–49 group. Conclusions Overall, has significantly increased over within Research findings emphasize importance customized interventions aimed addressing issue thus contributing attainment Sustainable Development Goal 3 set by World Health Organization.

Language: Английский

Citations

45
Long term outcomes of patients with chronic kidney disease after COVID-19 in an urban population in the Bronx DOI Creative Commons
Jimmy Lu, Justin Y. Lu, Stephen Wang

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 19, 2025

Abstract We investigated the long-term kidney and cardiovascular outcomes of patients with chronic disease (CKD) after COVID-19. Our retrospective cohort consisted 834 CKD COVID-19 6,167 without between 3/11/2020 to 7/1/2023. Multivariate competing risk regression models were used estimate (as adjusted hazard ratios (aHR) 95% confidence intervals (CI)) progression a more advanced stage (Stage 4 or 5) major adverse events (MAKE), (MACE) at 6-, 12-, 24-month follow up. Hospitalized 12 24 months (aHR 1.62 CI[1.24,2.13] 1.76 [1.30, 2.40], respectively), but not non-hospitalized patients, higher compared those Both hospitalized MAKE 12- 24-months 1.73 [1.21, 2.50], 1.77 [1.34, 2.33], 1.31 [1.05, 1.64], MACE increases in CKD. These findings highlight need for close up care therapies that slow this high-risk subgroup.

Language: Английский

Citations

4
SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population DOI
Roham Hadidchi, Stephen Wang,

David Rezko

et al.

Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 86, P. 105613 - 105613

Published: April 8, 2024

Language: Английский

Citations

11
Cognitive Sequelae of COVID‐19: Mechanistic Insights and Therapeutic Approaches DOI Creative Commons
Yuhao Chen, Jing‐Shiun Jan, Chih‐Hao Yang

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2025, Volume and Issue: 31(3)

Published: March 1, 2025

ABSTRACT Background The COVID‐19 pandemic has left an indelible mark on the world, with mounting evidence suggesting that it not only posed acute challenges to global healthcare systems but also unveiled a complex array of long‐term consequences, particularly cognitive impairment (CI). As persistence post‐COVID‐19 neurological syndrome could evolve into next public health crisis, is imperative gain better understanding intricate pathophysiology CI in patients and viable treatment strategies. Methods This comprehensive review explores management across phases COVID‐19, from infection Long‐COVID, by synthesizing findings clinical, preclinical, mechanistic studies identify key contributors CI, as well current therapeutic approaches. Results Key mechanisms contributing include persistent neuroinflammation, cerebrovascular complications, direct neuronal injury, activation kynurenine pathway, psychological distress. Both pharmacological interventions, such anti‐inflammatory therapies agents targeting neuroinflammatory pathways, non‐pharmacological strategies, including rehabilitation, show promise addressing these challenges. Although much derived preclinical animal studies, provide foundational insights potential Conclusion By knowledge, this highlights importance COVID‐19‐related offers actionable for mitigation recovery community continues grapple pandemic's impact.

Language: Английский

Citations

0
Impact of COVID‐19 on long‐term outcomes in Parkinson's disease DOI Creative Commons
Roham Hadidchi,

Yousef Al‐Ani,

Hannah Piskun

et al.

European Journal of Neurology, Journal Year: 2025, Volume and Issue: 32(5)

Published: May 1, 2025

Abstract Objectives Patients with pre‐existing Parkinson's disease (PD) face higher risks of severe acute COVID‐19 outcomes than matched controls, but long‐term post‐COVID‐19 remain largely unknown. This study investigated clinical up to 3.5 years post‐infection in a Bronx inner‐city PD population. Methods retrospective evaluated 3512 patients the Montefiore Health System (January 2016–July 2023), which serves large diverse population and was an epicenter early pandemic subsequent infection surges. Comparisons were made without positive SARS‐CoV‐2 test (defined by polymerase chain reaction test). Outcomes post‐index date all‐cause mortality, major adverse cardiovascular events (MACE), altered mental status, fatigue, dyspnea, headache, psychosis, dementia, depression, anxiety, dysphagia, falls, orthostatic hypotension. Changes Levodopa prescriptions also tabulated. Adjusted hazard ratios (aHR) computed accounting for competing risks. Results had similar demographics prevalence comorbidities compared COVID‐19. greater risk mortality (aHR = 1.58 [95% CI: 1.03, 2.41]), MACE 1.57 [1.19, 2.07]), fall dose adjustment cohort. Conclusions Among patients, associated outcomes. who survive may benefit from heightened awareness close follow‐up. Findings highlight need improve post‐COVID care mitigate progression maintain quality life.

Language: Английский

Citations

0
Long-term outcomes of patients with Parkinson’s disease 3.5 years post SARS-CoV-2 infection in an inner-city population in the Bronx DOI
Roham Hadidchi,

Yousef Al‐Ani,

Hannah Piskun

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: May 28, 2024

Abstract Objectives. Although patients with pre-existing Parkinson’s disease (PD) are at a higher risk of severe acute COVID-19 outcomes compared to matched controls, the long-term PD post SARS-CoV2 infection largely unknown. This study investigated clinical up 3.5 years post-infection in an inner-city population Bronx, New York. Methods. retrospective evaluated 3,512 Montefiore Health System Bronx (January 2016 July 2023), which serves large Black and Hispanic was epicenter early pandemic subsequent surges infections. status defined by positive polymerase-chain-reaction test. Comparisons were made without Outcomes post-index date all-cause mortality, major adverse cardiovascular events (MACE), altered mental status, fatigue, dyspnea, headache, psychosis, dementia, depression, anxiety, dysphagia, falls, orthostatic hypotension. Changes Levodopa, medication, prescriptions also tabulated. Adjusted hazard ratios (aHR) computed accounting for competing risks. Results. About 14% had similar demographics but prevalence comorbidities neurological disorders COVID-19. greater mortality (aHR = 1.58 [95% CI:1.03,2.41] P 0.03), MACE (HR 1.57[95% CI:1.19,2.07], P < 0.005), dyspnea 1.44 [1.11,1.87], 0.01), fatigue 1.49 [1.12,1.97] headache 1.35 [1.01,1.80] 0.04), fall 1.39 [1.01, 1.92] 0.04) index-date. Levodopa equivalent dose adjustment cohort non-COVID-19 (P 0.04). Conclusions. worse Patients who survive may benefit from heightened awareness close follow-up.

Language: Английский

Citations

3
A Comprehensive Review of the Global Epidemiology, Clinical Management, Socio-Economic Impacts, and National Responses to Long COVID with Future Research Directions DOI Creative Commons

Xiufang Song,

Weiwei Song, Lizhen Cui

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(11), P. 1168 - 1168

Published: May 31, 2024

Long COVID, characterized by a persistent symptom spectrum following SARS-CoV-2 infection, poses significant health, social, and economic challenges. This review aims to consolidate knowledge on its epidemiology, clinical features, underlying mechanisms guide global responses;

Language: Английский

Citations

3
Tackling persistent neurological symptoms in patients following acute COVID-19 infection: an update of the literature DOI Creative Commons
Eder Cáceres, Afshin A. Divani, André Emilio Viñán Garcés

et al.

Expert Review of Neurotherapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 17

Published: Dec. 23, 2024

Introduction The COVID-19 pandemic has taught myriad lessons and left several questions we are yet to comprehend. Initially, the scientific community was concerned with management of acute disease immunization. Once peak receded, it became clear that a proportion patients were far from fully recovered. Researchers started recognize those persisting symptoms as new entity termed 'Long COVID,' where neurological evident have major impact on quality life.

Language: Английский

Citations

3
Long COVID-19 outcomes of patients with pre-existing dementia DOI Creative Commons
Roham Hadidchi,

Rachel Pakan,

Tharun T. Alamuri

et al.

Journal of Alzheimer s Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

Although COVID-19 has been linked to worse acute outcomes in patients with some neurodegenerative disorders, its long-term impact on dementia remains unclear.

Language: Английский

Citations

2
Mortality and COVID Infection: Predictors of Mortality 10 Months after Discharge DOI Creative Commons
Víctor Eugenio Vera-Delgado,

Dácil García-Rosado,

Onán Pérez‐Hernández

et al.

Diseases, Journal Year: 2024, Volume and Issue: 12(6), P. 123 - 123

Published: June 5, 2024

Background: The long-term survival of patients hospitalized with COVID-19 and the factors associated poorer months after infection are not well understood. aims present study were to analyze overall mortality 10 admission. Methods: 762 disease included. Patients underwent a complete clinical evaluation, routine laboratory analysis chest X-ray. Data collected included demographic data, such as vascular risk factors, tobacco or alcohol use, comorbidity, institutionalization. Results: Ten-month was 25.6%: 108 deaths occurred in-hospital, while 87 died discharge. In-hospital independently related NT-proBNP values > 503.5 pg/mL [OR = 4.67 (2.38–9.20)], urea 37 mg/dL [3.21 (1.86–7.31)] age older than 71 years 1.93 (1.05–3.54)]. 5.00 (3.06–8.19)], [3.51 (1.97–6.27)], cognitive impairment 1.96 (1.30–2.95), cancer 2.23 (1.36–3.68), leukocytes 6330/mm3 1.64 (1.08–2.50)], mortality. Conclusions: death remains high even infection. Overall during hospital discharge is nearly that observed Comorbidities impairment, organ dysfunction inflammatory reaction independent prognostic markers

Language: Английский

Citations

1